AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29996844 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day course of artemether-lumefantrine (AL)
Number of subjects: 154
Study 29996844 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of artemether-lumefantrine (AL)
Number of subjects: 154
Study 29996844 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (3-day and 5-day AL)
Number of subjects: 154
Study 29996844 — intervention group
Group type: EXPERIMENTAL
Intervention: k13 mutations
Number of subjects: 154
Study 28683766 — intervention group
Group type: EXPERIMENTAL
Intervention: ixazomib-Rd
Number of subjects: 115
Study 28683766 — intervention group
Group type: COMPARATOR
Intervention: placebo-Rd
Number of subjects: 115
Study 25577471 — intervention group
Group type: EXPERIMENTAL
Intervention: DiAlert intervention
Number of subjects: 96
Study 25577471 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 22841396 — intervention group
Group type: EXPERIMENTAL
Intervention: γ‐TmT supplementation
Number of subjects: 15
Study 22841396 — intervention group
Group type: COMPARATOR
Intervention: Control (no γ‐TmT supplementation)
Number of subjects: 15
Study 21726916 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone-metformin
Number of subjects: 68
Study 21726916 — intervention group
Group type: COMPARATOR
Intervention: glimepiride-metformin
Number of subjects: 68
Study 18653426 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (n = 22)
Number of subjects: 80
Study 18653426 — intervention group
Group type: COMPARATOR
Intervention: No intervention (n = 21)
Number of subjects: 80
Study 17126774 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Diprifusor) target-controlled infusion at a predetermined target concentration starting at 2.5 mug/mL; step size of 0.1 microg/mL
Number of subjects: 50
Study 17126774 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Diprifusor) target-controlled infusion
Number of subjects: 50
Study 14559317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil omega-3 fatty acids (4.5 g/d) + sulfasalazine (2 g/d)
Number of subjects: 9
Study 14559317 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (2 g/d) alone
Number of subjects: 9
Study 14559317 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 9
Study 10812331 — intervention group
Group type: EXPERIMENTAL
Intervention: UV radiation (UVR) exposure
Number of subjects: 30
Study 10812331 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin type I and II
Number of subjects: 30
Study 10812331 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoproduct repair rates at 24 h and 48 h after UV irradiation
Number of subjects: 30
Study 8857137 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/day)
Number of subjects: 33
Study 8857137 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 33
Study 1509401 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF (50 micrograms/m2)
Number of subjects: 6
Study 6374866 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine 400 mg twice daily
Number of subjects: 101
Study 6374866 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1 g daily
Number of subjects: 101
Study 6374866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 101
Study 31816478 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 71
Study 31816478 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (LTG)
Number of subjects: 71
Study 31816478 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine (OXC)
Number of subjects: 71
Study 30852132 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated structured weight-management programme
Number of subjects: 149
Study 30852132 — intervention group
Group type: COMPARATOR
Intervention: Best-practice care
Number of subjects: 149
Study 30007359 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness measured by CES-D
Number of subjects: 254
Study 30007359 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness measured by UCLA Loneliness Scale
Number of subjects: 254
Study 27670851 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 shocks/min
Number of subjects: 160
Study 27670851 — intervention group
Group type: COMPARATOR
Intervention: 60 shocks/min
Number of subjects: 160
Study 23314489 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 daily local mud packs and generalized thermal baths with sulfate‐calcium‐magnesium‐fluorides mineral water added to usual treatment
Number of subjects: 60
Study 23314489 — intervention group
Group type: COMPARATOR
Intervention: Regular outpatient care routine (exercise, NSAIDs and/or analgesics)
Number of subjects: 60
Study 23314489 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 daily local mud packs and generalized thermal baths
Number of subjects: 60
Study 22170369 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g WG/d for 16 wk
Number of subjects: 316
Study 22170369 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g WG/d for 8 wk followed by 120 g WG/d for 8 wk
Number of subjects: 316
Study 22170369 — intervention group
Group type: COMPARATOR
Intervention: Control (no dietary change)
Number of subjects: 316
Study 21126610 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI with enoxaparin and abciximab
Number of subjects: 205
Study 21126610 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis with enoxaparin and reteplase
Number of subjects: 205
Study 17703184 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV)
Number of subjects: 41
Study 17703184 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 41
Study 15786932 — intervention group
Group type: EXPERIMENTAL
Intervention: PADMA 28, 3 x 2 capsules daily for 4 weeks
Number of subjects: 60
Study 15786932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12040291 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administration at 7:00 am
Number of subjects: 20
Study 12040291 — intervention group
Group type: COMPARATOR
Intervention: G-CSF administration at 7:00 pm
Number of subjects: 20
Study 10341401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound during pregnancy
Number of subjects: 4715
Study 10341401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound during pregnancy (subgroup analysis among boys)
Number of subjects: 4715
Study 10341401 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analyses (exposure vs non-exposure)
Number of subjects: 4715
Study 10341401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 4715
Study 8543487 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg tds
Number of subjects: 864
Study 8543487 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 500 mg tds
Number of subjects: 864
Study 8543487 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg bd
Number of subjects: 864
Study 8543487 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg bd
Number of subjects: 864
Study 8543487 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 1 g tds
Number of subjects: 864
Study 1962599 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg once daily
Number of subjects: 254
Study 1962599 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg once daily
Number of subjects: 254
Study 1962599 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg once daily
Number of subjects: 254
Study 7046782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline 7.5 mg twice daily
Number of subjects: 20
Study 7046782 — intervention group
Group type: COMPARATOR
Intervention: Ordinary terbutaline 5 mg three times daily
Number of subjects: 20
Study 31953730 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group
Number of subjects: 32
Study 31953730 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained females
Number of subjects: 32
Study 31953730 — intervention group
Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 32
Study 29304772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (EDAl program)
Number of subjects: 349
Study 29304772 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 349
Study 26651453 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan for 12 weeks
Number of subjects: 56
Study 26651453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 25580717 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation task
Number of subjects: 110
Study 25580717 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 110
Study 23579367 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1107‐T5.0
Number of subjects: 130
Study 23579367 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1107‐T7.5
Number of subjects: 130
Study 23579367 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 130
Study 23579367 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (GC1107‐T5.0, GC1107‐T7.5, Control)
Number of subjects: 130
Study 19680279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (Avastin)
Number of subjects: 0
Study 19680279 — intervention group
Group type: COMPARATOR
Intervention: Other treatment options (control group)
Number of subjects: 0
Study 18004683 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g.kg(‐1) BW NaHCO3 ingestion with passive recovery (BICARB P)
Number of subjects: 9
Study 18004683 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g.kg(‐1) BW NaHCO3 ingestion with active recovery (BICARB A)
Number of subjects: 9
Study 18004683 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion with passive recovery (PLAC P)
Number of subjects: 9
Study 18004683 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion with active recovery (PLAC A)
Number of subjects: 9
Study 16421365 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled hypertonic saline (5 ml of 7 percent sodium chloride) four times daily without amiloride pretreatment
Number of subjects: 24
Study 16421365 — intervention group
Group type: COMPARATOR
Intervention: Inhaled hypertonic saline with amiloride pretreatment
Number of subjects: 24
Study 16421365 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled hypertonic saline with placebo
Number of subjects: 24
Study 15556830 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5 mg and 25 mg once daily)
Number of subjects: 0
Study 15556830 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (200 mg once daily)
Number of subjects: 0
Study 15556830 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (4000 mg daily)
Number of subjects: 0
Study 15556830 — intervention group
Group type: COMPARATOR
Intervention: Nabumetone (1000 mg once daily)
Number of subjects: 0
Study 15556830 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5 mg)
Number of subjects: 0
Study 11475497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 0
Study 11475497 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 0
Study 8940983 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T
Number of subjects: 174
Study 8940983 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC
Number of subjects: 174
Study 8940983 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMP
Number of subjects: 174
Study 8940983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study 1307884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocean sounds played on the Marsona Sound Conditioner for three consecutive nights posttransfer from the ICU
Number of subjects: 60
Study 1307884 — intervention group
Group type: COMPARATOR
Intervention: No control of environment, except for the elimination of white noise
Number of subjects: 60
Study 3877303 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg bolus injection over 5 seconds
Number of subjects: 60
Study 3877303 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2 mg/kg bolus injection
Number of subjects: 60
Study 3877303 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kg and 2.0 mg/kg
Number of subjects: 60
Study 3877303 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion for maintenance of anaesthesia
Number of subjects: 60
Study 2887153 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% ALO 2145
Number of subjects: 73
Study 2887153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 30102965 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of toreforant once daily through week 24
Number of subjects: 162
Study 30102965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 25773049 — intervention group
Group type: EXPERIMENTAL
Intervention: State mandates for coverage of colorectal, cervical, and prostate cancer screenings
Number of subjects: 0
Study 25773049 — intervention group
Group type: EXPERIMENTAL
Intervention: Coverage of preventive care (mandated or not)
Number of subjects: 0
Study 25773049 — intervention group
Group type: EXPERIMENTAL
Intervention: Users of cancer screening
Number of subjects: 0
Study 25773049 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-users of cancer screening
Number of subjects: 0
Study 24901463 — intervention group
Group type: EXPERIMENTAL
Intervention: Announced pill count
Number of subjects: 207
Study 24901463 — intervention group
Group type: EXPERIMENTAL
Intervention: PACTG adherence questionnaire
Number of subjects: 207
Study 24901463 — intervention group
Group type: EXPERIMENTAL
Intervention: Child self‐report
Number of subjects: 207
Study 22414520 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine anesthetic paste (TAP) applied to the maxillary mucobuccal fold
Number of subjects: 0
Study 22414520 — intervention group
Group type: COMPARATOR
Intervention: Benzocaine paste applied to the opposite side
Number of subjects: 0
Study 20731494 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Health and Development Program treatment group
Number of subjects: 461
Study 20731494 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 461
Study 19035431 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 86
Study 19035431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 15671258 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (vitamin supplementation)
Number of subjects: 4060
Study 12759558 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label nortriptyline (NT) treatment for 6 weeks
Number of subjects: 92
Study 12759558 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cholesterol levels
Number of subjects: 92
Study 12759558 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine treatment for 8 weeks (control group)
Number of subjects: 92
Study 10698385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 45
Study 10698385 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide 20 ppm
Number of subjects: 45
Study 10698385 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide 40 ppm
Number of subjects: 45
Study 9114142 — intervention group
Group type: EXPERIMENTAL
Intervention: Stibogluconate + Allopurinol
Number of subjects: 0
Study 9114142 — intervention group
Group type: COMPARATOR
Intervention: Stibogluconate
Number of subjects: 0
Study 8240434 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 64
Study 8240434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 2870222 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg three times a day)
Number of subjects: 6
Study 2870222 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg twice a day)
Number of subjects: 6
Study 2870222 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 6
Study 2870222 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of verapamil
Number of subjects: 6
Study 31213227 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple exemplar condition
Number of subjects: 132
Study 31213227 — intervention group
Group type: COMPARATOR
Intervention: Low-word overlap condition
Number of subjects: 132
Study 31213227 — intervention group
Group type: COMPARATOR
Intervention: High-word overlap condition
Number of subjects: 132
Study 29439994 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture treatment
Number of subjects: 30
Study 29439994 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 27260196 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 199
Study 24140220 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous antibiotics
Number of subjects: 1640
Study 24140220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1640
Study 22569086 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 569
Study 22569086 — intervention group
Group type: COMPARATOR
Intervention: Iron‐folic acid supplementation
Number of subjects: 569
Study 22569086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study 20536364 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 170
Study 20536364 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 170
Study 17490928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg daily for 12 weeks)
Number of subjects: 19
Study 17490928 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (10 mg daily for 12 weeks)
Number of subjects: 19
Study 17490928 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without diabetes)
Number of subjects: 19
Study 16198879 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time 3D Doppler echocardiography
Number of subjects: 50
Study 16198879 — intervention group
Group type: COMPARATOR
Intervention: 2-dimensional echocardiography
Number of subjects: 50
Study 11833827 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 to 300 mg/d
Number of subjects: 238
Study 11833827 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 to 20 mg/d
Number of subjects: 238
Study 11109752 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 50
Study 11109752 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 50
Study 8625624 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% low‐molecular‐weight hydroxyethyl starch solution
Number of subjects: 42
Study 8625624 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin
Number of subjects: 42
Study 8625624 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of pentoxifylline (1.4 mg/kg/hr iv)
Number of subjects: 42
Study 1526697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocryptine
Number of subjects: 52
Study 1526697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31056081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabrief pulse bitemporal ECT (3 times seizure threshold)
Number of subjects: 36
Study 31056081 — intervention group
Group type: COMPARATOR
Intervention: Brief pulse bitemporal ECT (1.5 times seizure threshold)
Number of subjects: 36
Study 31237107 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-cognitive training
Number of subjects: 76
Study 31237107 — intervention group
Group type: COMPARATOR
Intervention: Documentary videos (Control)
Number of subjects: 76
Study 29070639 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month workplace intervention programme with environmental changes
Number of subjects: 0
Study 29070639 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving three times feedback of the assessment of physical activity and basic occupational health service
Number of subjects: 0
Study 26184841 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg
Number of subjects: 32
Study 26184841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 24135509 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 432
Study 24135509 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 432
Study 21892106 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: 40 Gy/20 fractions/4 weeks with concurrent weekly vinorelbine 25 mg/m + cisplatin 20 mg/m
Number of subjects: 84
Study 21892106 — intervention group
Group type: COMPARATOR
Intervention: Arm B: 30 Gy/15 fractions/3 weeks with concurrent weekly gemcitabine 200 mg
Number of subjects: 84
Study 19393989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alpha‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 30
Study 19393989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17043069 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic mode switching (AMS) of pacemakers
Number of subjects: 57
Study 12775784 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and physical exercise programme (8 sessions of 2 hours each)
Number of subjects: 126
Study 10689005 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg vaginally)
Number of subjects: 12
Study 10689005 — intervention group
Group type: COMPARATOR
Intervention: Prometrium (100 mg orally)
Number of subjects: 12
Study 9034811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0
Study 8480507 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 27
Study 8480507 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 27
Study 3688071 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast stimulation test
Number of subjects: 50
Study 3688071 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin challenge test
Number of subjects: 50
Study 28920756 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone Replacement Therapy (TRT)
Number of subjects: 48